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Abstract
One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is
the  increased  expression  of  AR  variants  lacking  the  ligand  binding-domain,  the  best
characterized  of  which  is  AR-V7.  We  have  previously  reported  that  Phosphatidylinositol--
-phosphate 5-kinase alpha (PIP5Ka), is a lipid kinase that links to CDK1 and AR pathways. The
discovery of PIP5Ka inhibitor highlight the potential of PIP5K1α as a drug target in PCa. In this
study, we show that AR-V7 expression positively correlates with PIP5K1α in tumor specimens
from PCa patients. Overexpression of AR-V7 increases PIP5K1α, promotes rapid growth of PCa in
xenograft mice, whereas inhibition of PIP5K1α by its inhibitor ISA-2011B suppresses the growth
and invasiveness of xenograft tumors overexpressing AR-V7. PIP5K1α is a key co-factor for both
AR-V7 and AR, which are present as protein-protein complexes predominantly in the nucleus of
PCa  cells.  In  addition,  PIP5K1α  and  CDK1  influence  AR-V7  expression  also  through  AKT-
associated mechanism dependent on PTEN-status. ISA-2011B disrupts protein stabilization of
AR-V7 which is dependent on PIP5K1α, leading to suppression of invasive growth of AR-V7-high
tumors in xenograft mice. Our study suggests that combination of enzalutamide and PIP5K1α
may have a significant impact on refining therapeutic strategies to circumvent resistance to
antiandrogen therapies.
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